ABT vs AIZ Stock Comparison

Scores Breakdown

Metric	ABT	AIZ
📈 Growth	18/30	26/30
💰 Profitability	17/20	14/20
🏦 Financial Health	18/20	15/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	4/10	3/10
Overall Score	71/100	74/100

Side-by-Side Summaries

ABT Analysis	AIZ Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Over the 8 quarters, Revenues rose from about $2.967B in 2024 Q3 to $3.454B in 2026 Q2, roughly a 16% gain. Net Income advanced from about $133.8M to $298.6M, more than doubling, signaling improving operating leverage though occasional quarterly pauses (notably late 2025). The trend is broadly upward, supported by positive cash flow and expanding profits. 💰 Margins & Cash Flow Gross margin has hovered in the mid-to-high single digits to low double digits, averaging around 8–11%, with margin expansion by 2026. Operating margin followed suit, with 2026 Q2 showing about 11% OPM on revenue of $3.45B. Cash flow remains robust: Net cash from operating activities was strong in multiple quarters (e.g., 2026 Q2 ≈ $454.4M; 2026 Q1 ≈ $240.3M), while investing cash flow was negative as growth initiatives continued. Net cash flow overall was positive in several quarters. 🛡️ Balance Sheet & Liquidity Total assets (~~$36B) exceed liabilities (~~$30B), and equity sits around $6B, yielding a comfortable balance sheet. Current assets cover current liabilities, and there is minimal noncurrent debt, with steady operating cash flow underpinning liquidity. ⚠️ Key Drivers & Risks Drivers: Steady premium revenue growth; improving operating leverage. Risks: Catastrophe/claims volatility and regulatory/interest-rate sensitivity; competitive pricing pressure.

ABT Analysis

AIZ Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Over the 8 quarters, Revenues rose from about $2.967B in 2024 Q3 to $3.454B in 2026 Q2, roughly a 16% gain. Net Income advanced from about $133.8M to $298.6M, more than doubling, signaling improving operating leverage though occasional quarterly pauses (notably late 2025). The trend is broadly upward, supported by positive cash flow and expanding profits.

💰 Margins & Cash Flow

Gross margin has hovered in the mid-to-high single digits to low double digits, averaging around 8–11%, with margin expansion by 2026. Operating margin followed suit, with 2026 Q2 showing about 11% OPM on revenue of $3.45B. Cash flow remains robust: Net cash from operating activities was strong in multiple quarters (e.g., 2026 Q2 ≈ $454.4M; 2026 Q1 ≈ $240.3M), while investing cash flow was negative as growth initiatives continued. Net cash flow overall was positive in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets (~~$36B) exceed liabilities (~~$30B), and equity sits around $6B, yielding a comfortable balance sheet. Current assets cover current liabilities, and there is minimal noncurrent debt, with steady operating cash flow underpinning liquidity.

⚠️ Key Drivers & Risks

Drivers: Steady premium revenue growth; improving operating leverage.
Risks: Catastrophe/claims volatility and regulatory/interest-rate sensitivity; competitive pricing pressure.

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"